![Page 1: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/1.jpg)
Complications in Type 1 Diabetes: Complications in Type 1 Diabetes:
NephropathyNephropathy
Peter A. Gottlieb, MDPeter A. Gottlieb, MDBarbara Davis CenterBarbara Davis Center
University of Colorado Health Sciences Center University of Colorado Health Sciences Center Denver, CODenver, CO
![Page 2: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/2.jpg)
Why do complications occur?Why do complications occur?
• Insulin hypothesisInsulin hypothesis
• Glucose hypothesisGlucose hypothesis
• DCCT and many other studies support DCCT and many other studies support glucose hypothesisglucose hypothesis
![Page 3: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/3.jpg)
EDIC: Long Term Benefit of EDIC: Long Term Benefit of Intensive TreatmentIntensive Treatment
-The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9.
![Page 4: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/4.jpg)
EDIC: Long Term Benefit of EDIC: Long Term Benefit of Intensive TreatmentIntensive Treatment
-The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9.
![Page 5: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/5.jpg)
EDIC: Long Term Benefit of EDIC: Long Term Benefit of Intensive TreatmentIntensive Treatment
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-9.
![Page 6: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/6.jpg)
• Transient hyperglycemia leads to oxidative stress which increases complications
• Testing of this hypothesis is needed to determine if this is indeed true
![Page 7: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/7.jpg)
![Page 8: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/8.jpg)
Diabetic Nephropathy: Diabetic Nephropathy: PathogenesisPathogenesis
• Increased intraglomerular pressure
• Mesangial cell expansion• Reactive Oxygen Species (ROS)• Endothelial cell dysfunction• Increased Glomerular Basement
Membrane Thickness and Interstitial Fibrosis
![Page 9: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/9.jpg)
DETAIL Study: Head to Head DETAIL Study: Head to Head Comparison of ACE vs. ARB in Comparison of ACE vs. ARB in
Type 2 DNType 2 DN• 5 yr, prospective, multicenter,
randomized study in T2DM with HTN and early DN
• 120 subjects onTelmisartan 40-80 mg/day vs. 130 subjects on Enalapril 10-20 mg/day
• Primary endpoint: Change in GFR• Secondary endpoints: Change in
albuminuria, BP, CR, other CV outcome measures
![Page 10: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/10.jpg)
![Page 11: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/11.jpg)
DETAIL:DETAIL:Baseline CharacteristicsBaseline Characteristics
![Page 12: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/12.jpg)
DETAIL: Equivalent Protection from DETAIL: Equivalent Protection from ACE and ARB in Change GFRACE and ARB in Change GFR
![Page 13: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/13.jpg)
DETAIL: Key PointsDETAIL: Key Points
• Use of ACE or ARB slows down loss of GFR in T2DM with nephropathy
• Confirms previous shorter term studies
• Additional protection seen for CV complications
![Page 14: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/14.jpg)
ACE and ARB Lower Proteinuria ACE and ARB Lower Proteinuria better than ACE alone in T2DMbetter than ACE alone in T2DM
• Small 24 week study with 26 pts demonstrated that combination therapy of Losartan with Enalapril reduced proteinura greater than increased dose of Enalapril alone
• Blood pressure was similarly lowered in both groups
• CRP levels were lowered in combined treatment group, unchanged in ACE alone
• Other parameters measured were not significantly different between groups
Igarashi, et al, Endocrine Journal, 2006, epub
![Page 15: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/15.jpg)
Prevention and Treatment of Prevention and Treatment of Diabetic Nephropathy in T1DMDiabetic Nephropathy in T1DM
• Periodic screening for microalbuminuria – timed overnight samples beginning at 5 years from diagnosis
• Treatment of either microalbuminuria or HTN (to 120/80 or age-matched target) with ACE or ARB
• Use ACE or ARB, ACE with ARB and Diuretics, then consider other therapies based on clinical considerations
![Page 16: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/16.jpg)
How do complications occur?How do complications occur?
• Activation of Polyol PathwayActivation of Polyol Pathway• Accumulation of Advanced Glycosylation Accumulation of Advanced Glycosylation
End ProductsEnd Products• Protein Kinase C PathwayProtein Kinase C Pathway• Flux Through the Hexosamine PathwayFlux Through the Hexosamine Pathway• Oxygen Radicals and Enhanced Oxidative Oxygen Radicals and Enhanced Oxidative
StressStress• Altered Expression of Growth Factors and Altered Expression of Growth Factors and
Vasoactive Mediators Vasoactive Mediators
![Page 17: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/17.jpg)
Aldose Reductase and Aldose Reductase and Polyol PathwayPolyol Pathway
- Brownlee, M. Nature 2001 414:13 813-820.
![Page 18: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/18.jpg)
AGE PathwayAGE Pathway
- Brownlee, M. Nature 2001 414:13 813-820.
![Page 19: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/19.jpg)
How can we intervene?How can we intervene?• Polyol Pathway – Sorbinil, ZenarestatPolyol Pathway – Sorbinil, Zenarestat • Advanced Glycosylation End Products – Advanced Glycosylation End Products –
Aminoguanidine, sR RAGEAminoguanidine, sR RAGE• Protein Kinase C Pathway – Selective PKC Protein Kinase C Pathway – Selective PKC
inhibitors such as LY333531inhibitors such as LY333531• Flux through Hexamine – ?Flux through Hexamine – ?• Oxidative Stress – Vitamin C, Vitamin E, Oxidative Stress – Vitamin C, Vitamin E,
lipoic acidlipoic acid• Altered Expression of Growth Factors – Altered Expression of Growth Factors –
VEGF inhibitorsVEGF inhibitors
![Page 20: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/20.jpg)
Effect of Effect of -lipoic acid on -lipoic acid on experiemental diabetic retinopathyexperiemental diabetic retinopathy
Lin, et al, Diabetologia, 2006, 49:1089-1096
![Page 21: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/21.jpg)
Do they work?Do they work?
• Sorbinil, Zenarestat - Sorbinil, Zenarestat - Toxicity, IneffectiveToxicity, Ineffective • Aminoguanidine, sR RAGE - Aminoguanidine, sR RAGE - ??• PKC inhibitors - LY333531 - PKC inhibitors - LY333531 - MaybeMaybe• Flux through Hexamine – Flux through Hexamine – ??• Oxidative Stress – Vitamin C, Vitamin E, Oxidative Stress – Vitamin C, Vitamin E,
lipoic acid – lipoic acid – Small effect?Small effect?• Altered Expression of Growth Factors – Altered Expression of Growth Factors –
VEGF inhibitors - VEGF inhibitors - UnknownUnknown
![Page 22: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/22.jpg)
Why have our best efforts not Why have our best efforts not succeeded?succeeded?
• ToxicityToxicity• Drug Development – EfficacyDrug Development – Efficacy• Need to target multiple pathways at Need to target multiple pathways at
onceonce• Or something else?Or something else?
![Page 23: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/23.jpg)
Unified Theory of Unified Theory of ComplicationsComplications
- Brownlee, M. Nature 2001 414:13 813-820.
![Page 24: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/24.jpg)
Inhibition of GAPDH Affects Inhibition of GAPDH Affects Multiple Complication PathwaysMultiple Complication Pathways
- Du X, et al. J. Clin. Invest. 112:1049–1057 (2003).
![Page 25: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/25.jpg)
New Therapeutic ApproachesNew Therapeutic Approaches
• Glyceraldehyde-3-phosphate and fructose-6-Glyceraldehyde-3-phosphate and fructose-6-phosphate are major substrates for phosphate are major substrates for complication pathwayscomplication pathways
• Benfotiamine, is a derivative of the B vitamin Benfotiamine, is a derivative of the B vitamin thiaminethiamine
• Activates the thiamine dependent pentose Activates the thiamine dependent pentose phosphate enzyme transketolase which phosphate enzyme transketolase which converts these compounds away from these converts these compounds away from these pathwayspathways
• Affecting this pathway changes substrate Affecting this pathway changes substrate availability for polyol, hexosamine, availability for polyol, hexosamine, diacylglycerol (PKC), AGE pathway and NF-diacylglycerol (PKC), AGE pathway and NF-B signalingB signaling
![Page 26: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/26.jpg)
MMF and ACE synergize to MMF and ACE synergize to Reverse Experimental DNReverse Experimental DN
Wu, et al. Inflamm res. 2006. 192-199
![Page 27: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/27.jpg)
MMF and ACE synergize to MMF and ACE synergize to Reverse Experimental DNReverse Experimental DN
Wu, et al. Inflamm res. 2006. 192-199
TGFTGF
ED1ED1 MCP-1MCP-1
![Page 28: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/28.jpg)
Unified Theory of Unified Theory of ComplicationsComplications
- Brownlee, M. Nature 2001 414:13 813-820.
Benfotiamine
PARP inhibitors
![Page 29: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/29.jpg)
New Therapeutic ApproachesNew Therapeutic Approaches
• Molecules which can affect GAPDH activity
• Superoxide Dismutase
• Poly(ADPribose)polymerase (PARP) inhibitors, PJ34
![Page 30: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/30.jpg)
SummarySummary
• Tight control of blood sugars is the best Tight control of blood sugars is the best means to prevent and reverse complications means to prevent and reverse complications of diabetesof diabetes
• Reducing glycemic variability may also Reducing glycemic variability may also contribute to the development of contribute to the development of complications and can be achieved with complications and can be achieved with CGMSCGMS
• Therapies such as PKC inhibitors which Therapies such as PKC inhibitors which attack single pathways may be of benefitattack single pathways may be of benefit
• New therapeutic approaches which can target New therapeutic approaches which can target multiple pathways simultaneously may offer multiple pathways simultaneously may offer the best chance to prevent complicationsthe best chance to prevent complications
![Page 31: Complications in Type 1 Diabetes: Nephropathy](https://reader036.vdocument.in/reader036/viewer/2022062410/56815a68550346895dc7b5a5/html5/thumbnails/31.jpg)
Thank youThank you